PR Newswire Clinical TrialsOriginal article
Aqua Medical Names Bob Haggerty CEO to Take on Type 2 Diabetes
Trial StartPIMAPositive
AI Analysis
Summary
Aqua Medical names MedTech veteran Bob Haggerty as CEO as the company treats its first patient in a U.S. pilot study of PIMA for type 2 diabetes.
Clinical Trial Data
Outcome Details
First patient treated in U.S. pilot study
Importance:3/10
Sentiment:
0.40
ManagementClinical TrialType 2 DiabetesMedTechCEO Appointment
Read the original article
Published by PR Newswire Clinical Trials on August 4, 2026 2:00 PM